SCHEMBL21484899

SCHEMBL21484899

CC(=O)Nc1cccc(/C=C(\C#N)C(=O)Nc2nc(-c3ccccc3)cs2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.53
SMN1; SMN2 Q16637 8/20 0.53
ALDH1A1 P00352 6/20 0.53
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
LMNA P02545 4/20 0.53
HTT P42858 2/20 0.53
MAPK1 P28482 1/20 0.53
KDM4E B2RXH2 2/20 0.52
NPC1 O15118 6/20 0.50
RAB9A P51151 6/20 0.50
NFKB1 P19838 3/20 0.50
NFKB2 Q00653 3/20 0.50
RELA Q04206 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
POLB P06746 1/20 0.49
ABL1 P00519 2/20 0.48
ADORA3 P0DMS8 1/20 0.48
SIRT5 Q9NXA8 1/20 0.48
ROCK2 O75116 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484901 1.00 MAPT (0.53) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL21484718 0.89 KMT2A (0.59) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL28511750 0.86 KDM4E (0.52) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL28511749 0.86 KDM4E (0.52) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL21484909 0.85 LMNA (0.51) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL21484907 0.85 LMNA (0.51) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL21484841 0.85 EGFR (0.48) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL21484778 0.83 ERBB2 (0.51) MAPTMEN1KMT2ALMNAMAPK1
SCHEMBL21484629 0.82 EGFR (0.62) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL21484792 0.82 EGFR (0.53) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 MAPT 706/4885SMN1; SMN2 104/4885ALDH1A1 2267/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 MAPT 706/4885SMN1; SMN2 104/4885ALDH1A1 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.